| 2024/04/22 17:35:11 | |
|---|---|
| Price | |
| 8.226 EUR | |
| Difference | -1.44% (-0.12) |
General attributes
| ISIN | ES0171996087 |
| Symbol | GRF |
| Exchange | BME Continuous Market |
| Currency | EUR |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 5,003 EUR |
| Benchmark | IBEX 35 |
Market data
| Bid (Bid size) | - |
| Ask (Ask size) | - |
| Open | 8.43 EUR |
| High | 8.488 EUR |
| Low | 8.206 EUR |
| Close (prev. day) | 8.346 EUR |
| VWAP | 8.272321 EUR |
| Volume (pcs) | 2,744,119 |
| Trading volume | 22,700,233.51 |
| Number of trades | 3,593 |
| Last size | - |
Futures and Options
| Related Futures | 38 |
| Related Options | - |
PDF Downloads
| Company report: GRIFOLS SA |  |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Recent research
| Date | Headline | Download | |
| 2024/04/03 |
|
Global Equity Ratings |
|
| 2024/03/13 |
|
Global Equity Ratings |
|
| 2024/02/22 |
|
Global Equity Ratings |
|
| 2024/02/14 |
|
Global Equity Ratings |
|
| 2024/01/23 |
|
Global Equity Ratings |
|
| 2024/04/22 17:35:11 | |
|---|---|
| Price | |
| 8.226 EUR | |
| Difference | -1.44% (-0.12) |
General attributes
| ISIN | ES0171996087 |
| Symbol | GRF |
| Exchange | BME Continuous Market |
| Currency | EUR |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 5,003 EUR |
| Benchmark | IBEX 35 |
Market data
| Bid (Bid size) | - |
| Ask (Ask size) | - |
| Open | 8.43 EUR |
| High | 8.488 EUR |
| Low | 8.206 EUR |
| Close (prev. day) | 8.346 EUR |
| VWAP | 8.272321 EUR |
| Volume (pcs) | 2,744,119 |
| Trading volume | 22,700,233.51 |
| Number of trades | 3,593 |
| Last size | - |
Performance and Risk
| 6m | 1Y | 3Y | |
| Perf (%) | -21.17% | -12.90% | -65.22% |
| Perf (abs.) | -2.21 | -1.22 | -15.42 |
| Beta | 2.59 | 1.86 | 1.05 |
| Volatility | 103.63 | 77.09 | 55.95 |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Price data
| Ø price 5 days | Ø volume 5 days (pcs.) | 8.544 EUR (2,510,224) |
| Ø price 30 days | Ø volume 30 days (pcs.) | 8.403 EUR (4,541,288) |
| Ø price 100 days | Ø volume 100 days (pcs.) | 10.529 EUR (4,048,418) |
| Ø price 250 days | Ø volume 250 days (pcs.) | 11.419 EUR (2,382,380) |
| YTD High | date | 15.630 EUR (2024/01/02) |
| YTD Low | date | 6.362 EUR (2024/03/06) |
| 52 Weeks High | date | 15.920 EUR (2023/12/29) |
| 52 Weeks Low | date | 6.362 EUR (2024/03/06) |
All listings for GRIFOLS SA
| Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
| Vienna Stock Exchange | 2024/04/23 | 09:05 | 8.26 EUR | 0.00 | 2 |
| Tradegate | 2024/04/23 | 15:38 | 8.622 EUR | 0.27 | 42 |
| Stuttgart | 2024/04/23 | 11:49 | 8.61 EUR | 0.00 | 2 |
| Munich | 2024/04/23 | 08:02 | 8.338 EUR | 0.00 | 1 |
| London Stock Exchange European Trade Reporting | 2024/04/23 | 08:59 | 8.351 EUR | 0.00 | 1 |
| Hanover | 2024/04/23 | 08:00 | 8.20 EUR | 0.00 | 1 |
| Frankfurt | 2024/04/23 | 08:26 | 8.20 EUR | 0.00 | 1 |
| FINRA other OTC Issues | 2024/03/12 | 15:43 | 8.46 USD | 0.01 | 4 |
| Duesseldorf | 2024/04/23 | 12:31 | 8.65 EUR | 0.00 | 3 |
| Berlin | 2024/04/23 | 15:44 | 8.594 EUR | 0.00 | 10 |
| BME Continuous Market | 2024/04/22 | 17:35 | 8.226 EUR | 22.70 | 3,593 |
Company Logo
Contact Details
| GRIFOLS SA |
| - - |
| Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan - 08174 Barcelona |
| Telefon: +34-93-571-02-21 |
| Fax: +34-93-571-02-67 |
| E-mail: - |
PDF Downloads
| Company report: GRIFOLS SA | |
Company Profile
Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain. |
Members of Management Board
| Thomas Glanzmann | Chairman of Managing Board |
| Raimon Grifols Roura | Member of Executive Committee |
| Víctor Grífols Deu | Member of Executive Committee |
Board of directors
| Thomas Heinrich Glanzmann | Chairman of Supervisory Board |
| Enriqueta Felip Font | Member of Supervisory Board |
| Albert Coma-Cros | Member of Supervisory Board |
| Carina Szpilka Lázaro | Member of Supervisory Board |
| James Costos | Member of Supervisory Board |
| Montserrat Muñoz Abellana | Member of Supervisory Board |
| Raimon Grifols Roura | Member of Supervisory Board |
| Susana González Rodríguez | Member of Supervisory Board |
| Tomás Dagá Gelabert | Member of Supervisory Board |
| Victor Grifols Deu | Member of Supervisory Board |
| Íñigo Sánchez-Asiaín Mardones | Member of Supervisory Board |